Coulston James 4

What Happened James Coulston, Chief Financial Officer of ProKidney Corp. (PROK), was granted derivative awards covering 600,000 shares on March 1, 2026. The Form 4 reports an acquisition price of $0.00 (derivative), indicating a grant of options/awards rather than an open-market purchase or sale. The award vests in substantially equal monthly installments over a four-year period beginning March 1, 2026.

Key Details

• Transaction date: 2026-03-01; Transaction type/code: Grant/Award (A), listed as derivative.
• Reported amount: 600,000 shares; acquisition price shown as $0.00 on the Form 4.
• Vesting: Options vest in substantially equal monthly installments over four years beginning 3/1/2026 (see footnote).
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timing: Form filed 2026-03-03 for a 2026-03-01 transaction — appears to have been filed timely (within the typical 2-business-day window).

Context This was a compensation-related grant (derivative/option award), not a market buy or sale, so the shares are not immediately owned or tradable until they vest. Such awards are common for executives and reflect pay structure rather than a direct market signal.